Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.
Astonishing advances in life sciences and biotechnology have created a whole new industry with tremendous growth potential and far reaching consequences for the way we live. A particularly exciting area where innovative research is contributing to new knowledge is reproductive health. Advances in this area will bring improvements in fertility treatments, more convenient contraceptives, novel treatments for gynecological disorders, and innovative obstetric products. Ardana was created in 2000 to meet the needs of this reproductive health market estimated to be worth £10.2 billion per year.
Ardana was established to commercialize research undertaken at the Medical Research Council's Human Reproductive Sciences Unit (HRSU). The HRSU has been at the forefront of research in the human reproductive system for the last 30 years, and the unit is one of only four academic centers of excellence in human reproductive biology in the world.
Since its inception, Ardana has raised £34.6 million in three funding rounds. Ardana investors include Techno Venture Management, Merlin Biosciences, MVM, ABN-AMRO Capital, 3i, ISIS Equity Partners, Scottish Widows Investment Partnership, Mitsubishi, and Green Highlander.
Ardana is a global company in the truest sense of the word. The company, which is based in the center of Edinburgh's stunning new town, collaborates with companies across the globe. The excellence of the science undertaken at the HRSU and Ardana's close links with other local centers of excellence, such as the University of Edinburgh Department of Obstetrics and Gynecology, make Edinburgh a strong location for the company.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.